Emyria secures local MDMA to start PTSD clinical trial dosing

Latest News

Emyria (ASX:EMD) has announced that it has secured a locally available supply of MDMA through a collaboration with Mind Medicine Australia (MMA) and the Australian National University (ANU).

The company said the supply ensures the timely commencement of its ethics-approved MDMA-assisted therapy (MDMA-AT) trial (EMDMA-001) while awaiting a comprehensive shipment from Canada.

Emyria CEO Dr Michael Winlo said, "With our recent milestones, including the Pax Centre acquisition, our team's training, and ethics approval, MDMA supply was the final component. We are grateful to MMA and the ANU for their support in securing an immediately available initial supply which ensures we can continue progress while we wait for our subsequent larger shipment from Canada pending approval from Health Canada.”

The School of Medicine at the Australian National University is spearheading the creation of a patient registry in Australia. The registry aims to gauge the effectiveness and safety of psychedelic substances when used therapeutically for severe mental health conditions, including depression and post-traumatic stress disorder. It will aggregate and analyse real-world data from clinical practice involving MDMA and psilocybin.

The ANU's Professor Paul Fitzgerald said, "Australia's approach to regulated psychedelic use is unique and forward-thinking. Our collaboration with Emyria will help us to expand our knowledge base, capturing insights beyond the controlled environment of clinical trials. This partnership aims to deepen our understanding of the real-world impact of these therapies."